一个抗体可以治疗所有
1Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA 94720, USA.
概括
保存的黄病毒蛋白对开发广泛有效的疫苗和治疗各种黄病毒感染有希望. 这一发现可能会导致针对登革热和寨卡病毒等疾病的多功能治疗策略.
科学领域:
- 病毒学
- 免疫学
- 疫苗开发
背景情况:
- 流感病毒,如登革热病毒 (DENV) 和寨卡病毒 (ZIKV),对全球健康构成重大威胁.
- 目前的疫苗和疗法通常是针对病毒的,因此需要开发更广泛的对策.
- 通过在各类黄病毒中保存蛋白质的目标,可以实现多功能疫苗和治疗策略.
研究的目的:
- 识别和描述flavivirus属内的保存蛋白目标.
- 评估这种保存蛋白作为广泛抗病毒干预的目标的潜力.
- 探索对开发多功能的疫苗和治疗 flavivirus 感染的影响.
主要方法:
- 在多种类型的黄病毒中对保存的蛋白序列进行生物信息分析.
- 鉴定出保存的黄病毒蛋白的蛋白质表达和净化.
- 免疫学测定以评估抗体结合和中和潜力.
- 在体外和体内研究以评估治疗效果.
主要成果:
- 在主要的人类病原性黄状病毒中,发现一种特定的黄状病毒蛋白质具有高度保护性.
- 这种保存的蛋白质显示出产生交叉中和抗体的显著潜力.
- 临床前研究表明,向这种蛋白质可以提供对多种状病毒的保护.
结论:
- 鉴定出保存的黄病毒蛋白质是开发多功能疫苗的有希望的目标.
- 向这种蛋白质可能会导致针对一系列黄病毒疾病的新疗法.
- 对这种保存的蛋白质进行进一步的研究可能会加速制造广泛的病毒对策.
相关概念视频
Antibody Actions
1.5K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.5K
Cross-reactivity
31.6K
Overview
31.6K
Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
Humoral Immune Responses
77.6K
Overview
77.6K
Hybridoma Technology
15.5K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.5K


